Ireland
--:--IST
Recruiting Phase 1

Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study

NCT07332260 · tracked via the Priya Life Science Norway tracker
Phase
Phase 1
Started
2026-05
Last updated
2026-04-22

Condition(s) studied

Alzheimer s DiseaseFaecal Microbiota Transplantation (FMT)

Investigational drug(s) / intervention(s)

Biological: Preprocessed thawed donor FMT

Biological: Preprocessed thawed donor FMT: Biological: Preprocessed FMT solution is administered to the right side of the colon during a colonoscopy.

Study summary

The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Alzheimer's dementia mild to moderate stage * Presence of Alzheimer pathology core 1 biomarkers as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (2024) * Capable of giving informed consent Exclusion Criteria: * Contraindications for colonoscopy examination * Contraindications for Magnetic Resonance Imaging (MRI) * Life expectancy \< 1 year * Clinical frailty scale 7 or more * History of seizure disorder * History of brain tumour or intracranial bleed * Major psychiatric disorder such as schizophrenia, bipolar disorder, or major depressive disorder * Alcohol or substance abuse * Decompensated heart disease * Malignancy * Current use of anticoagulant treatment (dual acting oral anticoagulant or warfarin) * Pregnant or planning pregnancy * Colonic adenomas over 1 cm, tumours or signs of active colitis on colonoscopy * Status after colectomy or hemicolectomy * Inflammatory bowel disease * Immunocompromised individual * Receiving biological/antibody treatment

Primary outcome measure(s)

  • Incidence of treatment-related adverse events and serious adverse events. [Safety] — From baseline to 3 months after faecal microbiota transplantation
    Incidence of adverse events (AE) and serious adverse events (SAE). AE and SAE are evaluated by review of the medical record, questions of AE and SAE in person or by telephone, and AE and SAE forms.
  • Rate of participant recruitment [Feasibility] — 1 year
    Number of weeks needed to include ten participants for study intervention group
  • Number participants that complete colonoscopy [Feasibility] — 1 year
    Number of participants that complete colonoscopy
  • Time used per intervention [Feasibility] — 1 year
    Time given in hours and minutes of total time used for intervention per participant including colonoscopy and faecal microbiota transplantation.
  • Number that meet study eligibility [Feasibility] — 1 year
    Number of participants who are screened for study eligibility. Number who meet inclusion and exclusion criteria.
  • Number that complete study [Feasibility] — Baseline and 3 months after study intervention
    Proportion of participants enrolled that complete the study follow-up.
  • Engraftment of faecal microbiota transplantation (FMT) — baseline and 3 months after study intervention
    Comparison of the taxonomic composition of the microbiome in participants faecal samples at baseline and 3 months after FMT, with donor faecal sample. Metagenomic sequencing of faecal samples will be used.

Trial sites (1)

FacilityCityRegionStatus
University Hospital of North Norway, Tromsø Tromsø Troms Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07332260 on ClinicalTrials.gov ↗ ← All trials in Norway